| scholarly article | Q13442814 |
| P2093 | author name string | Martin PM | |
| Spyratos F | |||
| Gentile A | |||
| Bouchet C | |||
| Hacène K | |||
| Oglobine J | |||
| P2860 | cites work | Protein and messenger RNA levels of plasminogen activators and inhibitors analyzed in 22 human tumor cell lines | Q63915567 |
| Plasminogen activator system in human breast cancer | Q67743622 | ||
| The plasminogen activation system in human colon cancer: messenger RNA for the inhibitor PAI-1 is located in endothelial cells in the tumor stroma | Q67919702 | ||
| Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer | Q68357717 | ||
| Increase of urokinase-type plasminogen activator gene expression in human lung and breast carcinomas | Q68998787 | ||
| ISMOD: an all-subsets regression program for generalized linear models. I. Statistical and computational background | Q69055553 | ||
| Plasminogen activators and tumor development in the human colon: activity levels in normal mucosa, adenomatous polyps, and adenocarcinomas | Q69204552 | ||
| Plasminogen activator inhibitor 1 and plasminogen activator inhibitor 2 in various disease states | Q70386474 | ||
| Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer | Q70565913 | ||
| Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years | Q24680218 | ||
| A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding | Q25938984 | ||
| Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients | Q33190800 | ||
| Synthesis of fibrinolytic activator and inhibitor by endothelial cells | Q35051369 | ||
| Relationship between cathepsin D, urokinase, and plasminogen activator inhibitors in malignant vs benign breast tumours | Q35993235 | ||
| Plasminogen activators, tissue degradation, and cancer | Q39476382 | ||
| The relevance of plasminogen activators to neoplastic growth. A review of recent literature. | Q39526019 | ||
| Do proteases play a role in cancer invasion and metastasis? | Q39669635 | ||
| Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1. | Q41206436 | ||
| Role of the urokinase receptor in facilitating extracellular matrix invasion by cultured colon cancer | Q41674938 | ||
| Plasminogen activator inhibitor 1 in human carcinoma tissues | Q41679028 | ||
| Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas | Q42131114 | ||
| Type-1 plasminogen activator inhibitor in human breast carcinomas | Q43624221 | ||
| Multiparametric Prognostic Evaluation of Biological Factors in Primary Breast Cancer | Q44050631 | ||
| Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer | Q44212210 | ||
| ISMOD: an all-subsets regression program for generalized linear models. II. Program guide and examples | Q44718325 | ||
| Breast cancer prognostic factors: evaluation guidelines. | Q55052359 | ||
| Biological and clinical relevance of the urokinase-type plasminogen activator (uPA) in breast cancer | Q59287828 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | plasminogen | Q107129060 |
| P304 | page(s) | 398-405 | |
| P577 | publication date | 1994-02-01 | |
| P1433 | published in | British Journal of Cancer | Q326309 |
| P1476 | title | Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas | |
| P478 | volume | 69 |
| Q44439079 | A High Cytosol Value of Urokinase-Type Plasminogen Activator (uPA) May Be Predictive of Early Relapse in Primary Breast Cancer |
| Q35196548 | Angiogenesis and antiangiogenic strategies in pancreatic cancer |
| Q60907892 | Association of uPA and PAI-1 tumor levels and 4G/5G variants of PAI-1 gene with disease outcome in luminal HER2-negative node-negative breast cancer patients treated with adjuvant endocrine therapy |
| Q42522659 | Blood and tissue fibrinolytic profiles in patients with colorectal carcinoma. |
| Q34033291 | Can axillary dissection be avoided by improved molecular biological diagnosis? |
| Q36620181 | Cathepsin-D, urokinase plasminogen activator and type-1 plasminogen activator inhibitor in early breast cancer: an immunohistochemical study of prognostic value and relations to tenascin-C and other factors |
| Q35745390 | Cellular distribution and clinical value of urokinase-type plasminogen activator, its receptor, and plasminogen activator inhibitor-2 in esophageal squamous cell carcinoma |
| Q35616321 | Chemical strategies for activity-based proteomics |
| Q71089140 | Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: an immunohistochemical comparison of normal, benign, and malignant breast tissues |
| Q36421968 | Contribution of plasminogen activators and their inhibitors to the survival prognosis of patients with Dukes' stage B and C colorectal cancer |
| Q73515400 | Correlation of tissue and blood plasminogen activation system in breast cancer |
| Q36291662 | Development of a new metastatic human breast carcinoma xenograft line |
| Q36622861 | Differential regulation of cell proliferation and protease secretion by epidermal growth factor and amphiregulin in tumoral versus normal breast epithelial cells |
| Q37203214 | Down-regulation of SerpinB2 is associated with gefitinib resistance in non-small cell lung cancer and enhances invadopodia-like structure protrusions |
| Q73025879 | Elevations of tissue-type plasminogen activator and differential expression of urokinase-type plasminogen activator in diseased aorta |
| Q24533487 | Enzyme activity profiles of the secreted and membrane proteome that depict cancer cell invasiveness |
| Q36840119 | Expression of urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in benign, borderline, malignant primary and metastatic ovarian tumors |
| Q36115751 | External quality assessment of trans-European multicentre antigen determinations (enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) in human breast cancer tissue extracts |
| Q40972502 | Genetic alterations in breast cancer. |
| Q53318958 | High tumor tissue concentration of plasminogen activator inhibitor 2 (PAI-2) is an independent marker for shorter progression-free survival in patients with early stage endometrial cancer. |
| Q53671085 | Impact of patient age on the outcome of primary breast carcinoma. |
| Q39712414 | In vitro inhibition of human malignant brain tumour cell line proliferation by anti-urokinase-type plasminogen activator monoclonal antibodies |
| Q47344852 | Increase of a urokinase receptor-related low-molecular-weight molecule in colorectal adenocarcinomas |
| Q71835777 | Influence of the extraction procedure on plasminogen activator inhibitor-2 (PAI-2) and urokinase receptor (uPAR) assays in breast cancer tissues |
| Q36641395 | Inhibition of apoptosis in human tumour cells by the tumour-associated serpin, SCC antigen-1. |
| Q78053624 | Invasion marker PAI-1 remains a strong prognostic factor after long-term follow-up both for primary breast cancer and following first relapse |
| Q47251534 | Larger and more invasive colorectal carcinoma contains larger amounts of plasminogen activator inhibitor type 1 and its relative ratio over urokinase receptor correlates well with tumor size |
| Q44611664 | Limited Prognostic Value of c-erbB-2 Compared to uPA and PAI-1 in Primary Breast Carcinoma |
| Q77540117 | Macrophage role in the anti-prostate cancer response to one class of antiangiogenic agents |
| Q53654445 | MiR-10a and miR-181c regulate collagen type I generation in hypertrophic scars by targeting PAI-1 and uPA. |
| Q33743421 | Modelling pulmonary microthrombosis coupled to metastasis: distinct effects of thrombogenesis on tumorigenesis |
| Q33922875 | New paradigms for the treatment of cancer: the role of anti-angiogenesis agents |
| Q34284270 | Node-Negative Breast Cancer: Which Patients Should Be Treated? |
| Q41062519 | Nutrition and breast cancer risk: can an effect via insulin resistance be demonstrated? |
| Q35980584 | Organ Specific Tumor Markers: What's New? |
| Q35495620 | Peroxisome Proliferator-Activated Receptor-γ Ligands Alter Breast Cancer Cell Motility through Modulation of the Plasminogen Activator System |
| Q47725947 | Physiological and pathological changes of plasma urokinase-type plasminogen activator, plasminogen activator inhibitor-1, and urokinase-type plasminogen activator receptor levels in healthy females and breast cancer patients |
| Q41100535 | Plasminogen activation on tumor cell surface and its involvement in human leukemia. |
| Q36430997 | Plasminogen activator inhibitor type 2 in breast cancer. |
| Q36430945 | Plasminogen activator inhibitor-1 (PAI-1) is not related to response to neoadjuvant chemotherapy in breast cancer |
| Q43760328 | Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer |
| Q42937214 | Plasminogen activator system, vascular endothelial growth factor, and colorectal cancer progression |
| Q24794845 | Prognostic molecular markers in early breast cancer |
| Q36292147 | Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer. |
| Q71089115 | Prognostic value of the plasminogen activation system in patients with gastric carcinoma |
| Q36617900 | Prognostic value of uPA and p53 accumulation measured by quantitative biochemical assays in 1245 primary breast cancer patients: a multicentre study. |
| Q36292537 | Prognostic value of urokinase plasminogen activator in primary breast carcinoma: comparison of two immunoassay methods |
| Q33838161 | Proteases in gastrointestinal neoplastic diseases |
| Q42095382 | Proteolysis in human breast and colorectal cancer |
| Q33918458 | Proteolysis in human breast cancer |
| Q64950341 | Quality control of immunohistochemical evaluation of tumour-associated plasminogen activators and related components. European BIOMED-1 Concerted Action on Clinical Relevance of Proteases in Tumour Invasion and Metastasis. |
| Q37189305 | Revisiting the biological roles of PAI2 (SERPINB2) in cancer |
| Q36617844 | Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: 6-year median follow-up |
| Q36114916 | Significance of plasminogen activator inhibitor 2 as a prognostic marker in primary lung cancer: association of decreased plasminogen activator inhibitor 2 with lymph node metastasis |
| Q22009110 | Suppression of breast cancer growth and metastasis by a serpin myoepithelium-derived serine proteinase inhibitor expressed in the mammary myoepithelial cells |
| Q41547351 | The biochemistry of cancer dissemination |
| Q33634208 | The plasmin cascade and matrix metalloproteinases in non-small cell lung cancer |
| Q40934291 | The plasminogen activation system in tumour invasion and metastasis |
| Q40573725 | The prognostic value of the soluble urokinase-type plasminogen activator receptor (s-uPAR) in plasma of breast cancer patients with and without metastatic disease |
| Q34165118 | The role and regulation of urokinase-type plasminogen activator receptor gene expression in cancer invasion and metastasis |
| Q33538432 | The urokinase plasminogen activator system as a target for prognostic studies in breast cancer |
| Q41522331 | The urokinase-type plasminogen activator system in cancer metastasis: A review |
| Q73793888 | The urokinase-type plasminogen activator system in resected non-small-cell lung cancer. Rotterdam Oncology Thoracic Study Group |
| Q47718780 | Tissue extraction procedures for investigation of urokinase plasminogen activator (uPA) and its inhibitors PAI-1 and PAI-2 in human breast carcinomas |
| Q73645160 | Topological localization of plasminogen activator inhibitor type 2 |
| Q36295115 | Transforming growth factor beta 1 and sodium butyrate differentially modulate urokinase plasminogen activator and plasminogen activator inhibitor-1 in human breast normal and cancer cells |
| Q33676610 | Urokinase plasminogen activator: a prognostic marker in multiple types of cancer |
| Q73503042 | Urokinase-type plasminogen activator receptor in gastric cancer: tissue expression and prognostic role |
| Q33779244 | microRNA-200c/141 upregulates SerpinB2 to promote breast cancer cell metastasis and reduce patient survival |
| Q35580701 | uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies |
Search more.